Business
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology
About this update from Neuropace, Inc.
[{"type":"text","content":"First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients MOUNTAIN VIEW, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a growth-stage medical technology company focused on transforming the lives of people living with epilepsy, today announced a first of its kind strategic collaboration that will leverage RNS System’s unique biomarker monitoring and data analysis capabilities. This collaboration will evaluate biomarker changes in currently implanted RNS System patients that have enrolled in a clinical-stage biotechnology company’s (“Company”) clinical trial of its product candidate. “This groundbreaking collaboration demonstrates the value that our RNS System can provide through its proven ability to collect and analyze data, which is then used to generate insights that can help inform treatment strategies,” said Joel Becker, President and Chief Executive Officer of NeuroPace. “We are excited to showcase the tremendous value of our data and look forward to further building on our artificial intelligence and machine learning capabilities to continue to harness the value of RNS System data in helping patients.” Under the terms of the agreement, NeuroPace will make available certain information and insights about currently implanted RNS System patients that have also enrolled in the Company’s Phase 2a proof-of-concept study and consented to providing the Company data obtained through their RNS Systems. Information provided by NeuroPace will be used by the Company to help them evaluate the impact of their product candidate on certain biomarkers of patients with focal onset seizures. NeuroPace anticipates the total revenue from this collaboration to be approximately $3.7 million. The Agreement is broken out into four phases through the fourth quarter of 2025, with certain milestones correlating to each phase, the majority of which are planned to be completed prior to the end of 2024. “Extending the benefit of the RNS System to improving clinical t...